RAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients

Journal of Dermatological Science

Volumn 61, Issue 3, 2011, Pages 194-198

  Roedl, Daniela ^a   Oji, Vinzenz ^b   Buters, Jeroen T M ^a   Behrendt, Heidrun ^a   Braun Falco, Markus ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adeno associated virus; Cornified envelope; Cutaneous gene therapy; Genodermatosis; Serine protease

Indexed keywords

COMPLEMENTARY DNA; LYMPHO EPITHELIAL KAZAL TYPE RELATED INHIBITOR; MESSENGER RNA; PARVOVIRUS VECTOR; PROTEIN LEKTI; PROTEIN SPINK5; SERINE PROTEASE INHIBITOR KAZAL TYPE 5; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; KERATINOCYTE; NETHERTON DISEASE; PLASMID; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; RECOMBINANT ADENO ASSOCIATED VIRUS 2; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; ADOLESCENT; BIOPSY; CELLS, CULTURED; CHILD; DNA, COMPLEMENTARY; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; INFANT; KERATINOCYTES; MALE; MUTATION; NETHERTON SYNDROME; PROTEINASE INHIBITORY PROTEINS, SECRETORY; TRANSFECTION;

EID: 79951580311     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.12.004     Document Type: Article

References (26)

1. Pruszkowski A., Bodemer C., Fraitag S., Teillac-Hamel D., Amoric J.C., de Prost V. Neonatal and infantile erythrodermas: a retrospective study of 51 patients. Arch Dermatol 2000, 136:875-880.
2. Judge M.R., Morgan G., Harper J.I. A clinical and immunological study of Netherton's syndrome. Br J Dermatol 1994, 131:615-621.
3. Chavanas S., Bodemer C., Rochat A., Hamel-Teillac D., Ali M., Irvine A.D., et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet 2000, 25:141-142.
4. Sprecher E., Chavanas S., DiGiovanna J.J., Amin S., Nielsen K., Prendiville J.S., et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001, 117:179-187.
5. Bitoun E., Chavanas S., Irvine A.D., Lonie L., Bodemer C., Paradisi M., et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 2002, 118:352-361.
6. Raghunath M., Tontsidou L., Oji V., Aufenvenne K., Schürmeyer-Horst F., Jajakumar A., et al. SPINK5 and Netherton Syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol 2004, 123:474-483.
7. Walden M., Kreutzmann P., Drogemüller K., John H., Forssmann W.G., Mägert H.-J. Biochemical features, molecular biology and clinical relevance of the human 15-domain serine proteinase inhibitor LEKTI. Biol Chem 2002, 383:1139-1141.
8. Bitoun E., Micheloni A., Lamant L., Bonnart C., Tartaglia-Polcini A., Cobbold C., et al. LEKTI proteolytic processiong in human primary keratinozytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 2003, 12:2417-2430.
9. Hachem J.P., Wagberg F., Schmuth M., Crumrine D., Lissens W., Jayakumar A., et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 2006, 126:1609-1621.
10. Deraison C., Bonnart C., Lopez F., Besson C., Robinson R., Jayakumar A., et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007, 18:3607-3619.
11. Descargues P., Deraison C., Prost C., Fraitag S., Mazereeuw-Hautier J., D'Alessio M., et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol 2006, 126:1622-1632.
12. Descargues P., Deraison C., Bonnart C., Kreft M., Kishibe M., Ishida-Yamamoto A., et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet 2005, 37:56-65.
13. Saif G.B., Al-Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int J Dermatol 2007, 46:290-294.
14. Renner E.D., Hartl D., Rylaarsdam S., Young M.L., Monaco-Shawver L., Kleiner G., et al. Comèl-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009, 124:536-543.
15. Braun-Falco M., Doenecke A., Smola H., Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Ther 1999, 6:432-441.
16. Braun-Falco M., Eisenried A., Büning H., Ring J. Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both ubiquitin/proteasome pathway and epidermal growth factor-receptor tyrosine kinase. Arch Dermatol Res 2005, 296:528-535.
17. Haug S., Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren-Larsson syndrome. Gene Ther 2006, 13:1021-1028.
18. Xiao X., Li J., Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998, 72:2224-2232.
19. Haug S., Braun-Falco M. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjögren-Larsson syndrome. Arch Dermatol Res 2005, 296:568-572.
20. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titers and yield. Gene Ther 1999, 6:973-985.
21. Komatsu N., Takata M., Otsuki N., Ohka R., Amano O., Takehara K., et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol 2002, 118:436-443.
22. Mazereeuw-Hautier J., Cope J., Ong C., Green A., Hovnanian A., Harper I. Topical recombinant alpha1-antitrypsin: a potential treatment for Netherton syndrome?. Arch Dermatol 2006, 142:396-397.
23. Mavilio F., Pellegrini G., Ferrari S., Nunio F., Di Iorio E., Recchia A., et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006, 12:1397-1402.
24. Briot A., Deraison C., Lacroix M., Bonnart C., Robin A., Besson C., et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009, 206:1135-1147.
25. Braun-Falco M., Rödl D. Recombinant adeno-associated virus vectors for somatic gene therapy in dermatology. Exp Rev Dermatol 2007, 2:153-165.
26. Foldvari M., Babiuk S., Badea I. DNA delivery for vaccination and therapeutics through the skin. Curr Drug Deliv 2006, 3:17-28.